Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Aug;68(2):380–384. doi: 10.1038/bjc.1993.344

Hormone resistant prostatic adenocarcinoma. An evaluation of prognostic factors in pre- and post-treatment specimens.

A Berner 1, J M Nesland 1, H Waehre 1, J Silde 1, S D Fosså 1
PMCID: PMC1968568  PMID: 7688548

Abstract

Pre- and post-treatment specimens from 47 patients with hormone resistant prostatic carcinoma were compared with each other regarding histological grade and immunoreactivity for p53 protein, neuron specific enolase and c-erbB-2 protein. Significantly more specimens expressed a high malignancy grade when the tumour had become hormone resistant than at the time of initial diagnosis (Gleason P: < 0.0001, WHO P:0.0003). p53 protein immunoreactivity increased significantly with disease progression (P:0.006), while tissue PSA immunoreactivity was reduced in post-treatment specimens (P:0.011). p53 protein expression did not correlate with histological grade or PSA expression and seems to be an independent parameter which participates late in the neoplastic transformation. Thirty-two percent of the tumours were neuron specific enolase positive, but this parameter did not correlate with development of hormone resistance. c-erbB-2 protein reactivity was not recognised.

Full text

PDF
380

Images in this article

381Figure 1
on p.381

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bazinet M., Hamdy S. M., Bégin L. R., Stephenson R. A., Fair W. R. Prognostic significance of antigenic heterogeneity, Gleason grade, and ploidy of lymph node metastases in patients with prostate cancer. Prostate. 1992;20(4):311–326. doi: 10.1002/pros.2990200406. [DOI] [PubMed] [Google Scholar]
  2. Berry W. R., Laszlo J., Cox E., Walker A., Paulson D. Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate. Cancer. 1979 Aug;44(2):763–775. doi: 10.1002/1097-0142(197908)44:2<763::aid-cncr2820440251>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  3. Brawn P. N. The dedifferentiation of prostate carcinoma. Cancer. 1983 Jul 15;52(2):246–251. doi: 10.1002/1097-0142(19830715)52:2<246::aid-cncr2820520210>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  4. Catalona W. J., Stein A. J., Fair W. R. Grading errors in prostatic needle biopsies: relation to the accuracy of tumor grade in predicting pelvic lymph node metastases. J Urol. 1982 May;127(5):919–922. doi: 10.1016/s0022-5347(17)54132-4. [DOI] [PubMed] [Google Scholar]
  5. Cohen R. J., Glezerson G., Haffejee Z. Neuro-endocrine cells--a new prognostic parameter in prostate cancer. Br J Urol. 1991 Sep;68(3):258–262. doi: 10.1111/j.1464-410x.1991.tb15318.x. [DOI] [PubMed] [Google Scholar]
  6. Effert P. J., Neubauer A., Walther P. J., Liu E. T. Alterations of the P53 gene are associated with the progression of a human prostate carcinoma. J Urol. 1992 Mar;147(3 Pt 2):789–793. doi: 10.1016/s0022-5347(17)37387-1. [DOI] [PubMed] [Google Scholar]
  7. Epstein J. I., Eggleston J. C. Immunohistochemical localization of prostate-specific acid phosphatase and prostate-specific antigen in stage A2 adenocarcinoma of the prostate: prognostic implications. Hum Pathol. 1984 Sep;15(9):853–859. doi: 10.1016/s0046-8177(84)80146-x. [DOI] [PubMed] [Google Scholar]
  8. Epstein J. I., Paull G., Eggleston J. C., Walsh P. C. Prognosis of untreated stage A1 prostatic carcinoma: a study of 94 cases with extended followup. J Urol. 1986 Oct;136(4):837–839. doi: 10.1016/s0022-5347(17)45097-x. [DOI] [PubMed] [Google Scholar]
  9. Ersev A., Ersev D., Turkeri L., Ilker Y., Simsek F., Kullu S., Akdas A. The relation of prostatic acid phosphatase and prostate specific antigen with tumour grade in prostatic adenocarcinoma: an immunohistochemical study. Prog Clin Biol Res. 1990;357:129–134. [PubMed] [Google Scholar]
  10. Feiner H. D., Gonzalez R. Carcinoma of the prostate with atypical immunohistological features. Clinical and histologic correlates. Am J Surg Pathol. 1986 Nov;10(11):765–770. doi: 10.1097/00000478-198611000-00003. [DOI] [PubMed] [Google Scholar]
  11. Grignon D., Troster M. Changes in immunohistochemical staining in prostatic adenocarcinoma following diethylstilbestrol therapy. Prostate. 1985;7(2):195–202. doi: 10.1002/pros.2990070209. [DOI] [PubMed] [Google Scholar]
  12. Gullick W. J., Love S. B., Wright C., Barnes D. M., Gusterson B., Harris A. L., Altman D. G. c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer. 1991 Mar;63(3):434–438. doi: 10.1038/bjc.1991.100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hale R. J., Buckley C. H., Fox H., Williams J. Prognostic value of c-erbB-2 expression in uterine cervical carcinoma. J Clin Pathol. 1992 Jul;45(7):594–596. doi: 10.1136/jcp.45.7.594. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Hammond M. E., Sause W. T., Martz K. L., Pilepich M. V., Asbell S. O., Rubin P., Myers R. P., Farrow G. M. Correlation of prostate-specific acid phosphatase and prostate-specific antigen immunocytochemistry with survival in prostate carcinoma. Cancer. 1989 Feb 1;63(3):461–466. doi: 10.1002/1097-0142(19890201)63:3<461::aid-cncr2820630312>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  15. Hsu S. M., Raine L., Fanger H. A comparative study of the peroxidase-antiperoxidase method and an avidin-biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies. Am J Clin Pathol. 1981 May;75(5):734–738. doi: 10.1093/ajcp/75.5.734. [DOI] [PubMed] [Google Scholar]
  16. Isaacs W. B., Carter B. S., Ewing C. M. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res. 1991 Sep 1;51(17):4716–4720. [PubMed] [Google Scholar]
  17. Johansson J. E., Adami H. O., Andersson S. O., Bergström R., Krusemo U. B., Kraaz W. Natural history of localised prostatic cancer. A population-based study in 223 untreated patients. Lancet. 1989 Apr 15;1(8642):799–803. doi: 10.1016/s0140-6736(89)92269-1. [DOI] [PubMed] [Google Scholar]
  18. Lange P. H., Narayan P. Understaging and undergrading of prostate cancer. Argument for postoperative radiation as adjuvant therapy. Urology. 1983 Feb;21(2):113–118. doi: 10.1016/0090-4295(83)90002-x. [DOI] [PubMed] [Google Scholar]
  19. Levine A. J., Momand J., Finlay C. A. The p53 tumour suppressor gene. Nature. 1991 Jun 6;351(6326):453–456. doi: 10.1038/351453a0. [DOI] [PubMed] [Google Scholar]
  20. Lundberg S., Carstensen J., Rundquist I. DNA flow cytometry and histopathological grading of paraffin-embedded prostate biopsy specimens in a survival study. Cancer Res. 1987 Apr 1;47(7):1973–1977. [PubMed] [Google Scholar]
  21. Matzkin H., Eber P., Todd B., van der Zwaag R., Soloway M. S. Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer. Cancer. 1992 Nov 1;70(9):2302–2309. doi: 10.1002/1097-0142(19921101)70:9<2302::aid-cncr2820700915>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  22. McCann A., Dervan P. A., Johnston P. A., Gullick W. J., Carney D. N. c-erbB-2 oncoprotein expression in primary human tumors. Cancer. 1990 Jan 1;65(1):88–92. doi: 10.1002/1097-0142(19900101)65:1<88::aid-cncr2820650119>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  23. McNeal J. E., Alroy J., Leav I., Redwine E. A., Freiha F. S., Stamey T. A. Immunohistochemical evidence for impaired cell differentiation in the premalignant phase of prostate carcinogenesis. Am J Clin Pathol. 1988 Jul;90(1):23–32. doi: 10.1093/ajcp/90.1.23. [DOI] [PubMed] [Google Scholar]
  24. McNeal J. E., Bostwick D. G., Kindrachuk R. A., Redwine E. A., Freiha F. S., Stamey T. A. Patterns of progression in prostate cancer. Lancet. 1986 Jan 11;1(8472):60–63. doi: 10.1016/s0140-6736(86)90715-4. [DOI] [PubMed] [Google Scholar]
  25. McNeal J. E., Price H. M., Redwine E. A., Freiha F. S., Stamey T. A. Stage A versus stage B adenocarcinoma of the prostate: morphological comparison and biological significance. J Urol. 1988 Jan;139(1):61–65. doi: 10.1016/s0022-5347(17)42293-2. [DOI] [PubMed] [Google Scholar]
  26. Mellon K., Thompson S., Charlton R. G., Marsh C., Robinson M., Lane D. P., Harris A. L., Horne C. H., Neal D. E. p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate. J Urol. 1992 Feb;147(2):496–499. doi: 10.1016/s0022-5347(17)37287-7. [DOI] [PubMed] [Google Scholar]
  27. Mulders P. F., Dijkman G. A., Fernandez del Moral P., Theeuwes A. G., Debruyne F. M. Analysis of prognostic factors in disseminated prostatic cancer. An update. Dutch Southeastern Urological Cooperative Group. Cancer. 1990 Jun 15;65(12):2758–2761. doi: 10.1002/1097-0142(19900615)65:12<2758::aid-cncr2820651225>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  28. Murphy G. P., Natarajan N., Pontes J. E., Schmitz R. L., Smart C. R., Schmidt J. D., Mettlin C. The national survey of prostate cancer in the United States by the American College of Surgeons. J Urol. 1982 May;127(5):928–934. doi: 10.1016/s0022-5347(17)54135-x. [DOI] [PubMed] [Google Scholar]
  29. O'Reilly S. M., Barnes D. M., Camplejohn R. S., Bartkova J., Gregory W. M., Richards M. A. The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer. Br J Cancer. 1991 Mar;63(3):444–446. doi: 10.1038/bjc.1991.102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Porter P. L., Gown A. M., Kramp S. G., Coltrera M. D. Widespread p53 overexpression in human malignant tumors. An immunohistochemical study using methacarn-fixed, embedded tissue. Am J Pathol. 1992 Jan;140(1):145–153. [PMC free article] [PubMed] [Google Scholar]
  31. Pretlow T. G., Pretlow T. P., Yang B., Kaetzel C. S., Delmoro C. M., Kamis S. M., Bodner D. R., Kursh E., Resnick M. I., Bradley E. L., Jr Tissue concentrations of prostate-specific antigen in prostatic carcinoma and benign prostatic hyperplasia. Int J Cancer. 1991 Nov 11;49(5):645–649. doi: 10.1002/ijc.2910490503. [DOI] [PubMed] [Google Scholar]
  32. Qiu S. D., Young C. Y., Bilhartz D. L., Prescott J. L., Farrow G. M., He W. W., Tindall D. J. In situ hybridization of prostate-specific antigen mRNA in human prostate. J Urol. 1990 Dec;144(6):1550–1556. doi: 10.1016/s0022-5347(17)39797-5. [DOI] [PubMed] [Google Scholar]
  33. Sawan A., Randall B., Angus B., Wright C., Henry J. A., Ostrowski J., Hennessy C., Lennard T. W., Corbett I., Horne C. H. Retinoblastoma and p53 gene expression related to relapse and survival in human breast cancer: an immunohistochemical study. J Pathol. 1992 Sep;168(1):23–28. doi: 10.1002/path.1711680105. [DOI] [PubMed] [Google Scholar]
  34. Smith J. A., Jr, Hernandez A. D., Wittwer C. J., Avent J. M., Greenwood J., Hammond E. H., Middleton R. G. Long-term follow-up after radical prostatectomy. Identification of prognostic variables. Urol Clin North Am. 1991 Aug;18(3):473–476. [PubMed] [Google Scholar]
  35. Stamey T. A., Yang N., Hay A. R., McNeal J. E., Freiha F. S., Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987 Oct 8;317(15):909–916. doi: 10.1056/NEJM198710083171501. [DOI] [PubMed] [Google Scholar]
  36. Stege R., Lundh B., Tribukait B., Pousette A., Carlström K., Hasenson M. Deoxyribonucleic acid ploidy and the direct assay of prostatic acid phosphatase and prostate specific antigen in fine needle aspiration biopsies as diagnostic methods in prostatic carcinoma. J Urol. 1990 Aug;144(2 Pt 1):299–302. doi: 10.1016/s0022-5347(17)39436-3. [DOI] [PubMed] [Google Scholar]
  37. Stege R., Tribukait B., Lundh B., Carlström K., Pousette A., Hasenson M. Quantitative estimation of tissue prostate specific antigen, deoxyribonucleic acid ploidy and cytological grade in fine needle aspiration biopsies for prognosis of hormonally treated prostatic carcinoma. J Urol. 1992 Sep;148(3):833–837. doi: 10.1016/s0022-5347(17)36736-8. [DOI] [PubMed] [Google Scholar]
  38. Vernon S. E., Williams W. D. Pre-treatment and post-treatment evaluation of prostatic adenocarcinoma for prostatic specific acid phosphatase and prostatic specific antigen by immunohistochemistry. J Urol. 1983 Jul;130(1):95–98. doi: 10.1016/s0022-5347(17)50977-5. [DOI] [PubMed] [Google Scholar]
  39. Waehre H., Wanderaas E. H., Paus E., Fosså S. D. Prediction of pelvic lymph node metastases by a prostate-specific antigen and prostatic acid phosphatase in clinical T3/T4M0 prostatic cancer. Eur Urol. 1992;22(1):33–38. doi: 10.1159/000474718. [DOI] [PubMed] [Google Scholar]
  40. Ware J. L., Maygarden S. J., Koontz W. W., Jr, Strom S. C. Immunohistochemical detection of c-erbB-2 protein in human benign and neoplastic prostate. Hum Pathol. 1991 Mar;22(3):254–258. doi: 10.1016/0046-8177(91)90159-m. [DOI] [PubMed] [Google Scholar]
  41. Whitmore W. F., Jr, Warner J. A., Thompson I. M., Jr Expectant management of localized prostatic cancer. Cancer. 1991 Feb 15;67(4):1091–1096. doi: 10.1002/1097-0142(19910215)67:4<1091::aid-cncr2820670437>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  42. Wright C., Mellon K., Neal D. E., Johnston P., Corbett I. P., Horne C. H. Expression of c-erbB-2 protein product in bladder cancer. Br J Cancer. 1990 Nov;62(5):764–765. doi: 10.1038/bjc.1990.375. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Wynford-Thomas D. P53 in tumour pathology: can we trust immunocytochemistry? J Pathol. 1992 Apr;166(4):329–330. doi: 10.1002/path.1711660402. [DOI] [PubMed] [Google Scholar]
  44. di Sant'Agnese P. A., de Mesy Jensen K. L. Neuroendocrine differentiation in prostatic carcinoma. Hum Pathol. 1987 Aug;18(8):849–856. doi: 10.1016/s0046-8177(87)80060-6. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES